The product comes from a substance so lethal that it could be used as a potential agent of bioterrorism.
The Price of Profits
Big drug companies today have remade their business models.
The Pfizer-Allergan merger is out, but what about inversions across the board?
A change in U.S. tax laws has put a halt to the merger.